中国药企发力研发创新药征募志愿者参加研究

2014-08-29 17:14:36来源：可可英语

　　Amid daily updates from the pharmaceuticalsindustry on the latest clinical trials, last week’sannouncement by Hutchison China MediTech that ithad enrolled patients for a study of colorectal cancerwas hardly cause for excitement.

　　在制药业每天都宣布最新临床试验的大背景下，和黄中国医药科技(Hutchison China MediTech)上周宣布已征募病患参加结直肠癌研究的消息，算不上令人振奋。

　　But it represented another step forward for one ofseveral experimental medicines that the company –backed by Li Ka-shing, Asia’s richest man – isdeveloping in China.

　　但这个消息反映出，亚洲首富李嘉诚(Li Ka-shing)支持的这家医药公司正在中国开发的几种试验药物之一又取得新进展。

　　With a market capitalisation of just £550m, London-listed China MediTech – known as Chi-Med– is not going to shake up “big pharma” overnight. However, it is part of a growing Chinese lifescience sector that the authorities in Beijing hope will become a force in drug development.

　　在伦敦上市的和黄中国医药市值仅5.5亿英镑，不会在一夜之间撼动大型制药商。然而，和黄中国医药是中国生命科学行业的一部分，而北京方面希望该行业能成为药物开发领域的一支力量。

　　“China realises that innovation is what matters in pharma,” says Christian Hogg, Chi-Med chiefexecutive. “There are already some big Chinese drug companies, but to get to the next levelthey have to innovate.”

　　“中国意识到，在制药业中，重要的是创新。”和黄中国医药首席执行官贺隽(Christian Hogg)表示，“中国已经有一些大型制药商，但要提升一个层次，它们就必须创新。”

　　Beijing has made faster development of research-based pharmaceuticals a national priority –both to serve the growing health demands of Chinese society, and to challenge thedominance of western drugmakers globally. In the government’s latest five-year plan, launchedin 2011, the sector was identified as one of seven “pillar” industries to be promoted.

　　北京方面已经将加快研发创新药列为国家重点工作，一方面是为了满足中国社会不断增长的健康需求，另一方面是为了挑战西方制药商在全球的主导地位。在2011年出台的“十二五”规划中，生物产业被列为要大力发展的七大“支柱”产业之一。

　　To the outside world, signs of progress have so far been limited. Several big foreigndrugmakers have opened research and development centres in China, or are planning to do so– including Novartis, Pfizer and Johnson & Johnson. But most homegrown Chinesecompanies are yet to move beyond low-value generic medicines or ingredients for innovativedrugs made in the US and Europe.

　　在外界看来，迄今没有多少迹象显示情况有重大进展。多家大型外资制药商在中国开设了研发中心，或是有这样做的计划，其中包括诺华(Novartis)、辉瑞(Pfizer)和强生(Johnson & Johnson)。但大多数中国本土制药商仍在生产低附加值的仿制药，或在为欧美生产的创新药供应配料。

本文关键字: 中国药企发力研发创新药